Chief Investigator for the study Dr Peter Trainer, Professor of Endocrinology, The Christie NHS
Foundation Trust, UK, said; ‘There are limited therapeutic options for patients with acromegaly and
there is an acknowledged need for new therapies. The results achieved in this Phase II trial suggest
ATL1103 with appropriate dose adjustment should be capable of achieving disease control in a
significant proportion of patients with acromegaly. ATL1103’s profile as a potentially efficacious and
well tolerated conveniently dosed therapy strongly supports its move into Phase III stage of
development.”
we made it !!!!!!
ANP Price at posting:
15.0¢ Sentiment: Buy Disclosure: Held
